RecruitingNCT07333547

Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform


Sponsor

Idoven 1903 S.L.

Enrollment

200,000 participants

Start Date

Feb 3, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The WILLEM Registry is a large-scale, single-group, observational, registry study to collect continuous clinical evidence of Willem in real-world settings. Cardiovascular diseases are a major problem for public health and healthcare systems. Electrocardiograms (ECGs) are simple tests which increase diagnostic performance and early detection of cardiovascular diseases. However, its interpretation is complex, time consuming for cardiology experts, and entails high costs for healthcare systems. Willem allows AI-based automatic interpretation and its performance has been examined in previous clinical trials, but additional clinical evidence is needed for its integration in real-world clinical settings. This study will collect clinical evidence of Willem performance to detect cardiac abnormalities in ECGs from high-risk cardiac patients admitted to cardiovascular units.


Eligibility

Min Age: 18 Years

Inclusion Criteria10

  • EC/IRB approval of ICF waiver prior to recruitment; otherwise, signed informed consent form by subject and investigator
  • Age > 18 years-old, with no upper limit
  • Subjects undergoing standard of care electrocardiogram (ECG) of any duration from any hardware device
  • All available, but at least one, legible ECG tracings in raw data format (e.g. DICOM, XML, EDF, JSON, HL7, SCP, WFDB, CSV, etc.)
  • Available subject clinical data associated with the ECG
  • For 12-lead ECGs, a minimum length of 10 seconds at a minimum sample frequency of 250 Hz
  • For ECGs from Holters, wearables, patches, insertable cardiac monitors, telemetries, etc., a minimum length of 30 seconds at a minimum sample frequency of 200 Hz with a lead I / II or its MCL-DII lead approximation
  • For prospective eligibility only:
  • Signed informed consent form, unless previously waived by the EC/IRB
  • Site technical viability for ECG and subject clinical data transfer (e.g. end-to-end integration following interoperability standards such as FHIR, HL7 or DICOM)

Exclusion Criteria2

  • Unavailable or suboptimal quality of the raw data from the ECG signal
  • Age < 18 years-old

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEWillem AI ECG assessment

There is no study intervention. The Willem AI platform will assess all study ECGs for the identification of cardiac patterns, arrhythmias, and/or cardiac diseases. Regardless of retrospective or prospective enrollment, Willem output will not be provided to the healthcare professional user for clinical evaluation, and therefore routine practice will not be impacted nor altered.


Locations(4)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

La Paz University Hospital

Madrid, Spain

Puerta de Hierro University Hospital

Madrid, Spain

Murcia University

Murcia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07333547